Search results for: EU HTA

Navigating the new EU HTA regulation: organisation...

Our latest article summarises the key changes to be aware of for the upcoming EU HTA, as well as imp...

EU HTA: moving from strategy to action

Remap Consulting guides participants through the intricacies of incorporating EU HTA considerations ...

EU HTA – moving from strategy to action for ...

ISPOR Europe 2023: Can Just Three PICOs be Feasibl...

This research aims to understand if just three PICOs are feasible by analysing recent HTA assessment...

ISPOR Europe 2023: How Aware Are Biotech and Pharm...

Our research aims to gauge awareness of the new EU HTA process within the pharmaceutical industry in...

Implications of the EU HTA Process for Manufacture...

Our experts discuss the latest news and updates on the EU HTA process, including implications for ma...

EU HTA and what it means for manufacturers

Oncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...

EU HTA – looking back on 2022

Our market access experts cover the changes to the joint EU HTA process that occurred in 2022 and wh...

Are you ready for the new EU HTA in 2025?

Webinar: Our experts discuss the latest news and updates on the EU HTA process, including the Joint ...

A single, mandatory HTA assessment for Europe

Over the last year, the European Commission (EC) has been consulting on multiple scenarios for HTA h...